The effect of whole body vibration therapy on older people
Completed
- Conditions
- Topic: Generic Health Relevance and Cross Cutting ThemesSubtopic: Generic Health Relevance (all Subtopics)Disease: Age and ageingInjury, Occupational Diseases, PoisoningFalling
- Registration Number
- ISRCTN19205068
- Lead Sponsor
- Kings College London (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
1. Men and women of all ages
2. Having had one or more falls
3. Attending the strength and balance group run in the Older Person Assessment Unit at Guy's Hospital
Exclusion Criteria
1. Artificial joints
2. Mini-mental state examination (MSSE) less than 20
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Physiological Profile Assessment, measured before and immediately upon completion of the exercise class
- Secondary Outcome Measures
Name Time Method 1. Six-metre walk test, measured at baseline, 4 and 8 weeks<br>2. Berg Balance Scale, measured at baseline, 4 and 8 weeks<br>3. Blood Analysis for markers of bone turnover, measured at baseline and 8 weeks<br>4. Falls Efficacy Scale - International (FES-I), measured at baseline and 8 weeks<br>5. 12-item short form health survey (SF12) version 2, measured at baseline and 8 weeks<br>6. Timed Up and Go Test, measured at baseline, 4weeks and 8 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie whole body vibration therapy (WBVT) effects on musculoskeletal health in older adults?
How does WBVT compare to standard fall prevention interventions like resistance training in elderly populations?
Are there specific biomarkers (e.g., myostatin, IL-6) that predict WBVT efficacy in sarcopenic or frail older individuals?
What adverse events are associated with WBVT in geriatric patients and how are they managed clinically?
Can WBVT be combined with anabolic agents or physical therapy to enhance mobility outcomes in age-related frailty?